[beta-Lactamase-inhibitor combinations].
Nakano
Ryuichi
R
Department of Microbiology, Kitasato University School of Medicine.
Okamoto
Ryoichi
R
D001419:Bacteria / Q000187:drug effects / Q000201:enzymology; D019818:Clavulanic Acid / Q000008:administration & dosage / Q000494:pharmacology; D015195:Drug Design; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination / Q000008:administration & dosage / Q000494:pharmacology; D006801:Humans; D010397:Penicillanic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D010406:Penicillins / Q000008:administration & dosage / Q000494:pharmacology; D013407:Sulbactam / Q000008:administration & dosage / Q000494:pharmacology; D000078142:Tazobactam; D065093:beta-Lactamase Inhibitors; D001618:beta-Lactamases / Q000145:classification
D010406:Penicillins; D065093:beta-Lactamase Inhibitors; D019818:Clavulanic Acid; D010397:Penicillanic Acid; D001618:beta-Lactamases; D013407:Sulbactam; D000078142:Tazobactam